Top stories in gastroenterology: Pregnant mothers’ diet may impact baby’s gut microbiome, no improvement in colectomy rates with accelerated Remicade induction

Among the top stories in gastroenterology is research that showed a child’s gut microbiome could be affected by their mother’s diet during pregnancy. Using an accelerated induction therapy of Remicade for a rescue treatment of acute severe ulcerative colitis did not help improve colectomy rates. Other top stories include endoscopic sleeve gastroplasty successfully treated obesity, chronic opioid use among patients with inflammatory bowel disease has become increasingly common, and patients who took Entyvio for the treatment of inflammatory bowel disease did not appear to have an increased risk for developing postoperative infections or other complications following nonintestinal surgery.

Pregnant mothers' diet may impact baby's gut microbiome

A mother’s diet during pregnancy might play a role in the makeup of her child’s gut microbiome, according to research published in Microbiome.

Accelerated Remicade induction offers no improvement in colectomy rates

Using accelerated induction therapy of Remicade for a rescue treatment of acute severe ulcerative colitis did not help improve colectomy rates compared with using a standard therapy, according to research published in Clinical Gastroenterology and Hepatology. Read More.

Endoscopic sleeve gastroplasty ready for implementation in clinic

Endoscopic sleeve gastroplasty – or ESG – successfully treated obesity in a new study showing its efficacy, safety and reproducibility outside the centers that launched the procedure years ago, according to research presented during Digestive Disease Week 2018. Read More.

Chronic opioid use increasingly common in younger IBD patients

Chronic opioid use among adolescent and young adult patients with inflammatory bowel disease has become increasingly common, according to research published in Inflammatory Bowel Diseases. Read More.

No increased infection risk after non-intestinal surgery while on biologic

Patients who took Entyvio for the treatment of inflammatory bowel disease did not appear to have an increased risk for developing postoperative infections or other complications following nonintestinal surgery, according to research published in Therapeutic Advances in Gastroenterology. Read More.